BridgeMD
Compares treatment options for Infertility; In Vitro Fertilization; Embryo Development
Official title Day-3 vs Day-5 Assisted Hatching: Impact on Blastocyst Morphology and PGT-A Outcomes
ClinicalTrials.gov ID: NCT07154875
What this study is testing
- What it's testing
- This randomized controlled trial evaluates the effect of assisted hatching (AH) timing on embryo development and genetic outcomes in in vitro fertilization (IVF) cycles with preimplantation genetic testing for aneuploidy (PGT-A). Eligible patients undergoing IVF with PGT-A will have embryos randomized to receive assisted hatching either on Day-3 or Day-5 of culture, prior to trophectoderm biopsy.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 45, women only
You may be able to join if
- IVF cycles with PGT-A
- Oocyte age 20-45 years (donor cycles: donor's age)
- AMH 1-10 ng/mL within 12 months
- AFC ≥5 follicles (2-9 mm, both ovaries, day 2-5)
- Controlled ovarian stimulation: antagonist or PPOS protocols
You likely can't join if
- History of ≥3 failed IVF cycles or ≥3 consecutive miscarriages
- Indication for PGT-M or PGT-SR (monogenic disorders, translocations)
- Severe medical/autoimmune conditions affecting oocytes/embryos (e.g. uncontrolled diabetes, active lupus)
- No MII oocytes available for ICSI
- Embryos not eligible for biopsy per SOP (early zona hatching, degeneration, poor expansion)
- Sperm from surgical retrieval or advanced sperm selection (IMSI, PICSI, MACS)
See the full eligibility criteria
- IVF cycles with PGT-A
- Oocyte age 20-45 years (donor cycles: donor's age)
- AMH 1-10 ng/mL within 12 months
- AFC ≥5 follicles (2-9 mm, both ovaries, day 2-5)
- Controlled ovarian stimulation: antagonist or PPOS protocols
- Stratified analysis by age (\<30, 30-34, 35-39, ≥40)
- Sperm source: ejaculated samples prepared by density-gradient or swim-up
- No surgical sperm retrieval
- No advanced sperm selection (IMSI, PICSI, MACS)
- History of ≥3 failed IVF cycles or ≥3 consecutive miscarriages
- Indication for PGT-M or PGT-SR (monogenic disorders, translocations)
- Severe medical/autoimmune conditions affecting oocytes/embryos (e.g. uncontrolled diabetes, active lupus)
- No MII oocytes available for ICSI
- Embryos not eligible for biopsy per SOP (early zona hatching, degeneration, poor expansion)
- Sperm from surgical retrieval or advanced sperm selection (IMSI, PICSI, MACS)
- PCOS diagnosed by Rotterdam criteria (≥2/3 features)
The study team makes the final eligibility decision.
Where it's taking place
- Hanoi, Hanoi, Vietnam
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 20 years to 45 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hanoi, Hanoi, Vietnam. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.